7 completed, 2 terminated, 1 withdrawn. 10 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 7, Terminated 2, Withdrawn 1 |
Follow nirmatrelvir: new trials by email Literature Review of nirmatrelvir trials Research Report on nirmatrelvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Healthy Participants Paxlovid, Nirmatrelvir/ritonavir - Biological Availability, Healthy Participants | Phase 1 | Withdrawn | Pfizer | 2025-08-15 | 2025-12-26 | |
| A Study to Learn About the Medicine (PF-07321332 or Nirmatrelvir/Ritonavir) in Healthy Lactating Women nirmatrelvir, ritonavir - Healthy Participants | Phase 1 | Completed | Pfizer | 8 | 2022-12-12 | 2026-05-01 |
| A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease PF-07321332 (nirmatrelvir)/ritonavir - COVID-19 | Phase 1 | Terminated | Pfizer | 15 | 2022-09-07 | 2024-09-23 |
| Bioequivalence Study of Nirmatrelvir & Ritonavir From Copaxid 150 +100 mg Tablets (Eva Pharma, Egypt) Versus Paxlovid 150 + 100 mg Film Coated Tablets (Pfizer Europe, Belgium) Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference first dose), Nirmatrelvir 150 mg + Ritonavir 100 mg (test), Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference second dose) - Healthy | Phase 1 | Completed | Genuine Research Center, Egypt | 28 | 2022-08-21 | 2023-01-18 |
| A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19 nirmatrelvir, ritonavir - COVID-19 | Phase 1 | Terminated | Pfizer | 25 | 2022-06-22 | 2026-08-17 |
| Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation PF-07321332/ritonavir, PF-07321332 - Bioavailability | Phase 1 | Completed | Pfizer | 12 | 2022-03-03 | 2025-06-11 |
| PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants Dabigatran, PF-07321332/ritonavir + Dabigatran, Ritonavir + Dabigatran - Healthy Participants | Phase 1 | Completed | Pfizer | 24 | 2021-09-21 | 2024-03-29 |
| Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy Participants Midazolam, PF-07321332/ritonavir + Midazolam, Ritonavir + Midazolam - Healthy Participants | Phase 1 | Completed | Pfizer | 12 | 2021-09-17 | 2023-10-04 |
| Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332 PF-07321332, Ritonavir - Hepatic Impairment | Phase 1 | Completed | Pfizer | 17 | 2021-08-31 | 2023-09-06 |
| Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function. PF-07321332/ritonavir - Renal Impairment | Phase 1 | Completed | Pfizer | 35 | 2021-06-15 | 2023-08-02 |
COVID-19 (9) · Renal Insufficiency (2) · Breast Feeding (1) · Kidney Diseases (1) · Severe Acute Respiratory Syndrome (1)
Pfizer (9) · Genuine Research Center, Egypt (1)
United States (6) · Belgium (2) · Egypt (1)
Ahmed Elshafeey, Ph.D. Pharma (1)
PMID 37231296, PMID 37354048, PMID 35712797, PMID 41823072, PMID 42012328
2023 (1)